/
Oncology
Multiple Myeloma
257
Pipeline Programs↗
613
Active Trials↗
188
Companies Involved↗
Multiple Myeloma is a highly competitive landscape with 257 programs across 188 companies. The most active players are AbbVie, GSK, Bristol-Myers Squibb. 51 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical49
Phase 170
Phase 287
Phase 351
Approved
No programs
Analysis
Modality Breakdown
64%
Small molecule
136 of 211 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 211 classified programs, each share of the total. Modality classified for 93% of 257 pipeline programs.
Analysis
Trial Status
2,041
clinical trials
Completed871 · 43%
Recruiting299 · 15%
Terminated278 · 14%
Active, not recruiting208 · 10%
Unknown status168 · 8%
Not yet recruiting104 · 5%
Other113 · 6%
Clinical Trials
Trial Activity
2041 trials
Page 1 of 137
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)